A subtype-specific impact on breast cancer survival was also noted for other constituents of the TF pathway, with F7 being associated with a better prognosis in the whole patient collective and the luminal A subtype, and F2R (PAR1)/F2RL1 (PAR2) acting as negative prognostic indicators particularly in the aggressive ER- and HER2 + subtypes. Here, F2RL1 is linked to breast cancer.